Bronx county has the country’s fifth-highest rate of HIV diagnosis—but the lowest rate in New York State for use of HIV pre-exposure prophylaxis (PrEP), medications that are extremely effective in preventing HIV infection. Physician-researchers at Albert Einstein College of Medicine and Montefiore Health System have received a five-year, $4.2 million grant from the National Institutes of Health to compare two strategies for improving PrEP access and use in the Bronx.
Special issue includes research and commentary addressing important considerations for national PrEP program that would lower prices and expand access.
A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.
Men at particular risk for HIV are very likely to consistently take prevention medication during vacations when their odds of contracting the virus are higher, according to a new study.
The Johns Hopkins School of Nursing @JHUNursing is hosting a Twitter Chat in advance of World AIDS Day featuring its practitioners, researchers, and experts in HIV care, prevention, and science. Tuesday, November 26, 4:00 pm, EST Join and ask questions…
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.